Bender Robert & Associates Sells 38 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bender Robert & Associates trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 422 shares of the company’s stock after selling 38 shares during the quarter. Bender Robert & Associates’ holdings in IDEXX Laboratories were worth $234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Moneta Group Investment Advisors LLC raised its holdings in IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after purchasing an additional 7,441,162 shares during the last quarter. Alliancebernstein L.P. raised its stake in IDEXX Laboratories by 6.4% during the second quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock worth $1,804,428,000 after buying an additional 214,529 shares during the last quarter. Geode Capital Management LLC lifted its holdings in IDEXX Laboratories by 1.4% in the first quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock valued at $971,569,000 after buying an additional 26,197 shares during the period. Blair William & Co. IL boosted its position in IDEXX Laboratories by 0.7% during the third quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock valued at $524,700,000 after acquiring an additional 7,812 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in IDEXX Laboratories by 2.2% during the 3rd quarter. Brown Advisory Inc. now owns 1,161,124 shares of the company’s stock worth $507,725,000 after acquiring an additional 24,741 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the transaction, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Insiders have sold a total of 43,524 shares of company stock valued at $24,871,960 in the last 90 days. 2.11% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on IDXX shares. The Goldman Sachs Group upped their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Barclays boosted their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. JPMorgan Chase & Co. lifted their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a research note on Tuesday, January 30th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

IDEXX Laboratories Stock Down 0.1 %

Shares of NASDAQ:IDXX traded down $0.45 during midday trading on Thursday, hitting $477.79. 396,748 shares of the company’s stock were exchanged, compared to its average volume of 427,323. The stock has a 50 day moving average price of $541.86 and a 200-day moving average price of $508.71. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The company has a market cap of $39.68 billion, a PE ratio of 47.49, a price-to-earnings-growth ratio of 3.77 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.05 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.